Combination antifungal therapy for mold infections: Much ado about nothing?

Research output: Contribution to journalReview article

34 Citations (Scopus)

Abstract

In general, mortality rates associated with systemic fungal infections have not improved much in more than a decade, although the number of antifungal agents available for the treatment of serious fungal infections has increased in the past few years. A possible approach to decreasing mortality rates associated with fungal infections may be to treat patients with combinations of different classes of antifungals. Recently, in vitro and animal studies evaluating different combinations of antifungal agents have demonstrated important synergistic and/or additive activity against many genera of fungi. However, prudence is required, because some antifungal combinations have demonstrated antagonistic activity. Well-controlled clinical trials are still necessary to define the most efficacious antifungal combination. In addition, these clinical trials should evaluate the adverse event profile of the combination regimens, as well as their pharmacoeconomic impact.

Original languageEnglish (US)
Pages (from-to)1889-1901
Number of pages13
JournalClinical Infectious Diseases
Volume46
Issue number12
DOIs
StatePublished - Jun 15 2008
Externally publishedYes

Fingerprint

Mycoses
Fungi
Antifungal Agents
Infection
Pharmaceutical Economics
Mortality
Controlled Clinical Trials
Therapeutics
Clinical Trials

ASJC Scopus subject areas

  • Infectious Diseases
  • Microbiology (medical)
  • Medicine(all)

Cite this

Combination antifungal therapy for mold infections : Much ado about nothing? / Vazquez, Jose Antonio.

In: Clinical Infectious Diseases, Vol. 46, No. 12, 15.06.2008, p. 1889-1901.

Research output: Contribution to journalReview article

@article{2e6e46307afd4f82ad3ffaaa5372208a,
title = "Combination antifungal therapy for mold infections: Much ado about nothing?",
abstract = "In general, mortality rates associated with systemic fungal infections have not improved much in more than a decade, although the number of antifungal agents available for the treatment of serious fungal infections has increased in the past few years. A possible approach to decreasing mortality rates associated with fungal infections may be to treat patients with combinations of different classes of antifungals. Recently, in vitro and animal studies evaluating different combinations of antifungal agents have demonstrated important synergistic and/or additive activity against many genera of fungi. However, prudence is required, because some antifungal combinations have demonstrated antagonistic activity. Well-controlled clinical trials are still necessary to define the most efficacious antifungal combination. In addition, these clinical trials should evaluate the adverse event profile of the combination regimens, as well as their pharmacoeconomic impact.",
author = "Vazquez, {Jose Antonio}",
year = "2008",
month = "6",
day = "15",
doi = "10.1086/588475",
language = "English (US)",
volume = "46",
pages = "1889--1901",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "12",

}

TY - JOUR

T1 - Combination antifungal therapy for mold infections

T2 - Much ado about nothing?

AU - Vazquez, Jose Antonio

PY - 2008/6/15

Y1 - 2008/6/15

N2 - In general, mortality rates associated with systemic fungal infections have not improved much in more than a decade, although the number of antifungal agents available for the treatment of serious fungal infections has increased in the past few years. A possible approach to decreasing mortality rates associated with fungal infections may be to treat patients with combinations of different classes of antifungals. Recently, in vitro and animal studies evaluating different combinations of antifungal agents have demonstrated important synergistic and/or additive activity against many genera of fungi. However, prudence is required, because some antifungal combinations have demonstrated antagonistic activity. Well-controlled clinical trials are still necessary to define the most efficacious antifungal combination. In addition, these clinical trials should evaluate the adverse event profile of the combination regimens, as well as their pharmacoeconomic impact.

AB - In general, mortality rates associated with systemic fungal infections have not improved much in more than a decade, although the number of antifungal agents available for the treatment of serious fungal infections has increased in the past few years. A possible approach to decreasing mortality rates associated with fungal infections may be to treat patients with combinations of different classes of antifungals. Recently, in vitro and animal studies evaluating different combinations of antifungal agents have demonstrated important synergistic and/or additive activity against many genera of fungi. However, prudence is required, because some antifungal combinations have demonstrated antagonistic activity. Well-controlled clinical trials are still necessary to define the most efficacious antifungal combination. In addition, these clinical trials should evaluate the adverse event profile of the combination regimens, as well as their pharmacoeconomic impact.

UR - http://www.scopus.com/inward/record.url?scp=46249101893&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46249101893&partnerID=8YFLogxK

U2 - 10.1086/588475

DO - 10.1086/588475

M3 - Review article

C2 - 18466092

AN - SCOPUS:46249101893

VL - 46

SP - 1889

EP - 1901

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 12

ER -